Johnson & Johnson has announced the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor $(CAR)$ T-cell therapy. This therapy is being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not previously undergone CAR T-cell therapy. The findings indicate a promising safety profile and suggest a 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose. These results were presented at the 2025 European Hematology Association (EHA) Congress. Further global clinical study data will be presented at the 2025 International Conference on Malignant Lymphoma, scheduled from June 17-21.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.